What Immunocore Holdings plc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 17 |
| Total trades | 0 | 32 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 32 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Goll John | SVP, FINANCE & CAO | Feb 18 | Sale for tax withholding · S | −698 | $32.35 | −$22.6K | 653 |
| St Leger Tina Amber | CHIEF HR OFFICER | Feb 18 | Sale for tax withholding · S | −1,000 | $32.35 | −$32.4K | 1,119 |
| Jallal Bahija | CHIEF EXECUTIVE OFFICER | Feb 18 | Sale for tax withholding · S | −11,474 | $32.35 | −$371K | 12,343 |
| Berman David M | HEAD OF R&D | Feb 18 | Sale for tax withholding · S | −5,965 | $32.35 | −$193K | 5,859 |
| Goll John | SVP, FINANCE & CAO | Feb 17 | Exercise / conversion · M | +1,351 | — | — | 1,351 |
| St Leger Tina Amber | CHIEF HR OFFICER | Feb 17 | Exercise / conversion · M | +2,119 | — | — | 2,119 |
| Jallal Bahija | CHIEF EXECUTIVE OFFICER | Feb 17 | Exercise / conversion · M | +23,817 | — | — | 23,817 |
| Berman David M | HEAD OF R&D | Feb 17 | Exercise / conversion · M | +11,824 | — | — | 11,824 |
| Berman David M | HEAD OF R&D | Dec 05 | Open-market sale · S | −572 | $40.14 | −$23K | 0 |
| Berman David M | HEAD OF R&D | Dec 05 | Exercise / conversion · M | +572 | $17.46 | +$9.99K | 572 |
| Berman David M | HEAD OF R&D | Dec 04 | Open-market sale · S | −31,341 | $40.26 | −$1.26M | 0 |
| Berman David M | HEAD OF R&D | Dec 04 | Exercise / conversion · M | +31,341 | $17.46 | +$547K | 31,341 |
| Berman David M | HEAD OF R&D | Nov 28 | Open-market sale · S | −5,521 | $40.09 | −$221K | 0 |
| Berman David M | HEAD OF R&D | Nov 28 | Exercise / conversion · M | +5,521 | $17.46 | +$96.4K | 5,521 |
| Berman David M | HEAD OF R&D | Nov 26 | Open-market sale · S | −69,404 | $40.12 | −$2.78M | 0 |
| Berman David M | HEAD OF R&D | Nov 26 | Exercise / conversion · M | +69,404 | $17.46 | +$1.21M | 69,404 |
| Berman David M | HEAD OF R&D | Nov 25 | Open-market sale · S | −18,020 | $40.03 | −$721K | 0 |
| Berman David M | HEAD OF R&D | Nov 25 | Exercise / conversion · M | +18,020 | $17.46 | +$315K | 18,020 |
| Berman David M | HEAD OF R&D | Nov 24 | Open-market sale · S | −100 | $40.00 | −$4K | 0 |
| Berman David M | HEAD OF R&D | Nov 24 | Exercise / conversion · M | +100 | $17.46 | +$1.75K | 100 |
Loading...